Key Takeaways AbbVie will pay up to $1.2B to acquire rights to bretisilocin from Gilgamesh.Bretisilocin showed rapid and durable antidepressant effects in phase II studyAbbVie continues neuroscience deal spree to strengthen its early-stage pipeline.AbbVie (ABBV) has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed for treating major depressive disorder(MDD).Gilgamesh is curr ...

NVIDIA RTX PRO Server NVIDIA RTX PRO Servers — a new category of enterprise data center infrastructure powered by the RTX PRO 6000 Blackwell Server Edition GPU. News Summary: Leading companies including Disney, Foxconn, Hitachi Ltd., Hyundai Motor Group, Lilly, SAP and TSMC are among the first to adopt NVIDIA RTX PRO Servers to speed AI reasoning, physical AI and business workloads.Enterprises are adopting NVIDIA RTX PRO Servers to transition from general-purpose clusters to AI factory infrastructure, w ...

Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial dataNAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms the Company ...

Psi-GAD delivers statistically significant and clinically meaningful improvements across validated measures of anxiety, mood, disability, and quality of life; results establish PSX-001 as a leading psilocybin-assisted therapy in development globallyMELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2 clinical trial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted psyc ...

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company pioneering therapies for central nervous system (CNS) disorders and advancing science-based consumer health solutions, today announced a pivotal expansion of its dual-path business model with the launch of its dedicated Nugevia™ e-commerce website, www.nugevia.com, and the opening of pre-order ...

Company advancing U.S. commercialization with FDA-approved ketamine and rare disorder NDA filingsTORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update highlighting commercial readiness for ketamine (KETARx™) and an ambitious regulatory program aimed at advancing KETARx™ for rare disorders. Fabio Ch ...

TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, proudly announced today that it had the honor of ringing the Closing Bell on Monday, 25 August, 2025, at the New York Stock Exchange (“NYSE”). This prestigious event marked a significant milestone in the Company’s journey to transform emergency medicine ...

No near-term Reverse Stock Split required to meet Bid Price RuleHOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it received a letter (the “Letter”) from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 5550(b). Specifically, the Letter confirms that the C ...

Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. Th ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Assertio Holdings, Inc. (ASRT) is a specialty pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 22.7% downward over the last 60 days.Black Stone Minerals, L.P. (BSM) owns and manages oil and natural gas mineral interests. The Zacks Consensus Estimate for its current year earnings has been revised 12.4% downward over the last 60 days.J&J Snack Foods Corp. (JJSF) is a packaged nutritiona ...